EUROLAB
usp-1099-acceptable-analytical-performance-criteria
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Complete Guide to USP <1099>: Acceptable Analytical Performance Criteria Testing Services Provided by Eurolab

USP <1099> is a laboratory testing service that evaluates the analytical performance of pharmaceutical and biopharmaceutical products. This standard is governed by the United States Pharmacopeia (USP), an independent, non-profit organization that develops standards for the pharmaceutical industry.

Legal and Regulatory Framework

The USP <1099> standard is mandated by regulatory agencies such as the US FDA, EMA, and WHO. Compliance with this standard is required for all pharmaceutical and biopharmaceutical products intended for human use in the United States, European Union, and other countries that adhere to these regulations.

International and National Standards

The following international standards apply to USP <1099> testing:

  • ISO 17025:2017 - General requirements for the competence of testing and calibration laboratories

  • ISO 15189:2012 - Medical laboratories - Requirements for quality and competence

  • ASTM E2653-13 - Standard practice for establishing a laboratory quality management system

  • EN ISO/IEC 17065:2012 - Conformity assessment - Requirements for bodies providing audit and certification of management systems

    • National standards may vary depending on the country or region. For example:

  • EU GMP (EU Good Manufacturing Practice) guidelines require compliance with USP <1099>

  • FDA guidelines for pharmaceutical quality control require adherence to USP <1099>

    • Standard Development Organizations

    Standard development organizations such as USP, ISO, and ASTM develop standards that govern laboratory testing services like USP <1099>. These organizations ensure that standards are updated regularly to reflect advances in technology and changes in regulatory requirements.

    Evolution of Standards

    Standards evolve over time due to advancements in technology, new scientific discoveries, or changes in regulatory requirements. Regular updates ensure that standards remain relevant and effective in ensuring product quality and safety.

    Standard Numbers and Scope

    The following standard numbers and scope apply to USP <1099> testing:

  • USP <1099>: Acceptable Analytical Performance Criteria

    • Scope: Evaluates the analytical performance of pharmaceutical and biopharmaceutical products

    Includes methods for determining limit of detection (LOD), limit of quantitation (LOQ), accuracy, precision, and specificity

    Industry-Specific Requirements

    Compliance with USP <1099> is required in various industries, including:

  • Pharmaceuticals: Manufacturers must ensure that their products meet the standards requirements to comply with regulatory agencies.

  • Biotechnology: Companies must demonstrate compliance with USP <1099> to maintain quality control and product safety.

    • Standard Compliance Requirements

    Regulatory agencies require compliance with USP <1099> standards for various reasons, including:

  • Ensuring product quality and safety

  • Maintaining public trust in pharmaceutical products

  • Preventing contamination or adulteration

    • Consequences of Non-Compliance

    Failure to comply with USP <1099> standards may result in:

  • Regulatory actions (e.g., fines, recalls)

  • Loss of market share and revenue

  • Damage to brand reputation and customer confidence

    • ---

    Why This Test is Needed and Required

    USP <1099> testing is essential for ensuring the quality and safety of pharmaceutical and biopharmaceutical products. The standard requires manufacturers to demonstrate the analytical performance of their products, which ensures that they meet regulatory requirements.

    Business and Technical Reasons

    Conducting USP <1099> testing provides several business and technical benefits:

  • Ensures compliance with regulatory agencies

  • Maintains quality control and product safety

  • Enhances public trust in pharmaceutical products

  • Prevents contamination or adulteration

    • Consequences of Not Performing This Test

    Failure to conduct USP <1099> testing may result in:

  • Regulatory actions (e.g., fines, recalls)

  • Loss of market share and revenue

  • Damage to brand reputation and customer confidence

    • Industries and Sectors Requiring This Testing

    The following industries require USP <1099> testing:

  • Pharmaceuticals: Manufacturers must ensure that their products meet the standards requirements.

  • Biotechnology: Companies must demonstrate compliance with USP <1099> to maintain quality control and product safety.

    • Risk Factors and Safety Implications

    Conducting USP <1099> testing mitigates various risk factors, including:

  • Contamination or adulteration of pharmaceutical products

  • Inaccurate or unreliable analytical results

  • Regulatory actions (e.g., fines, recalls)

  • Damage to brand reputation and customer confidence

    • Quality Assurance and Quality Control Aspects

    USP <1099> testing ensures quality control and product safety through:

  • Regular calibration and validation of equipment

  • Use of qualified and certified personnel

  • Maintenance of accurate records and documentation

  • Compliance with regulatory agencies requirements

    • ---

    USP <1099> is a laboratory testing service that evaluates the analytical performance of pharmaceutical and biopharmaceutical products. This standard is governed by the United States Pharmacopeia (USP), an independent, non-profit organization that develops standards for the pharmaceutical industry.

    Legal and Regulatory Framework

    The USP <1099> standard is mandated by regulatory agencies such as the US FDA, EMA, and WHO. Compliance with this standard is required for all pharmaceutical and biopharmaceutical products intended for human use in the United States, European Union, and other countries that adhere to these regulations.

    International and National Standards

    The following international standards apply to USP <1099> testing:

  • ISO 17025:2017 - General requirements for the competence of testing and calibration laboratories

  • ISO 15189:2012 - Medical laboratories - Requirements for quality and competence

  • ASTM E2653-13 - Standard practice for establishing a laboratory quality management system

  • EN ISO/IEC 17065:2012 - Conformity assessment - Requirements for bodies providing audit and certification of management systems

    • National standards may vary depending on the country or region. For example:

  • EU GMP (EU Good Manufacturing Practice) guidelines require compliance with USP <1099>

  • FDA guidelines for pharmaceutical quality control require adherence to USP <1099>

    • Standard Development Organizations

    Standard development organizations such as USP, ISO, and ASTM develop standards that govern laboratory testing services like USP <1099>. These organizations ensure that standards are updated regularly to reflect advances in technology and changes in regulatory requirements.

    Evolution of Standards

    Standards evolve over time due to advancements in technology, new scientific discoveries, or changes in regulatory requirements. Regular updates ensure that standards remain relevant and effective in ensuring product quality and safety.

    Standard Numbers and Scope

    The following standard numbers and scope apply to USP <1099> testing:

  • USP <1099>: Acceptable Analytical Performance Criteria

    • Scope: Evaluates the analytical performance of pharmaceutical and biopharmaceutical products

    Includes methods for determining limit of detection (LOD), limit of quantitation (LOQ), accuracy, precision, and specificity

    Industry-Specific Requirements

    Compliance with USP <1099> is required in various industries, including:

  • Pharmaceuticals: Manufacturers must ensure that their products meet the standards requirements to comply with regulatory agencies.

  • Biotechnology: Companies must demonstrate compliance with USP <1099> to maintain quality control and product safety.

    • Standard Compliance Requirements

    Regulatory agencies require compliance with USP <1099> standards for various reasons, including:

  • Ensuring product quality and safety

  • Maintaining public trust in pharmaceutical products

  • Preventing contamination or adulteration

    • Consequences of Non-Compliance

    Failure to comply with USP <1099> standards may result in:

  • Regulatory actions (e.g., fines, recalls)

  • Loss of market share and revenue

  • Damage to brand reputation and customer confidence

    • ---

    Why This Test is Needed and Required

    USP <1099> testing is essential for ensuring the quality and safety of pharmaceutical and biopharmaceutical products. The standard requires manufacturers to demonstrate the analytical performance of their products, which ensures that they meet regulatory requirements.

    Business and Technical Reasons

    Conducting USP <1099> testing provides several business and technical benefits:

  • Ensures compliance with regulatory agencies

  • Maintains quality control and product safety

  • Enhances public trust in pharmaceutical products

  • Prevents contamination or adulteration

    • Consequences of Not Performing This Test

    Failure to conduct USP <1099> testing may result in:

  • Regulatory actions (e.g., fines, recalls)

  • Loss of market share and revenue

  • Damage to brand reputation and customer confidence

    • Industries and Sectors Requiring This Testing

    The following industries require USP <1099> testing:

  • Pharmaceuticals: Manufacturers must ensure that their products meet the standards requirements.

  • Biotechnology: Companies must demonstrate compliance with USP <1099> to maintain quality control and product safety.

    • Risk Factors and Safety Implications

    Conducting USP <1099> testing mitigates various risk factors, including:

  • Contamination or adulteration of pharmaceutical products

  • Inaccurate or unreliable analytical results

  • Regulatory actions (e.g., fines, recalls)

  • Damage to brand reputation and customer confidence

    • Quality Assurance and Quality Control Aspects

    USP <1099> testing ensures quality control and product safety through:

  • Regular calibration and validation of equipment

  • Use of qualified and certified personnel

  • Maintenance of accurate records and documentation

  • Compliance with regulatory agencies requirements

    • ---

    Eurolabs Expertise in USP <1099> Testing

    At Eurolab, our team of experts is dedicated to providing high-quality analytical services for pharmaceutical and biopharmaceutical products. We have extensive experience with USP <1099> testing and can help you ensure compliance with regulatory agencies requirements.

    Our state-of-the-art facilities are equipped with the latest technology and equipment to perform precise and accurate analyses. Our team of experienced analysts is trained to follow strict protocols and procedures to ensure the integrity of your samples.

    Benefits of Choosing Eurolab

  • Expertise in USP <1099> testing

  • State-of-the-art facilities and equipment

  • Trained and certified personnel

  • Compliance with regulatory agencies requirements

  • Prompt turnaround times

    • Contact us today to learn more about our USP <1099> testing services and how we can help you maintain quality control and product safety.

    ---

    Conclusion

    USP <1099> testing is a critical component of pharmaceutical and biopharmaceutical product development. At Eurolab, our team of experts is dedicated to providing high-quality analytical services that ensure compliance with regulatory agencies requirements.

    We understand the importance of maintaining quality control and product safety in the pharmaceutical industry. Our state-of-the-art facilities and equipment are equipped to perform precise and accurate analyses, ensuring the integrity of your samples.

    Contact us today to learn more about our USP <1099> testing services and how we can help you maintain quality control and product safety.

    ---

    References

  • United States Pharmacopeia (USP). (2020). <1099>: Acceptable Analytical Performance Criteria.

  • International Organization for Standardization (ISO). (2017). ISO 17025:2017 - General requirements for the competence of testing and calibration laboratories.

  • European Medicines Agency (EMA). (2020). EU GMP Guidelines.

  • United States Food and Drug Administration (FDA). (2020). Pharmaceutical Quality/CMC.

    • Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers